The American Urological Association Education and Research (AUAER) has partnered with Pfizer Medical Grants & Partnerships (GMGP) to offer $1.5m in financing for advanced prostate cancer (APC).
The funding is intended to support urology and urologic oncology organisations.
The joint Request for Proposals (RFP) focuses on improving care for APC patients.
It aims to fund new projects that address critical care gaps and promote quality improvement and solution-based projects.
The RFP aims to inspire quality improvement projects that address barriers to optimal care. Projects focusing on disparities in advanced prostate cancer care are also encouraged.
American Urological Association said proposals should include teams with diverse perspectives and experience and offer sustainable, transferable solutions to enhance care quality.
American Urological Association education chair Jay Raman said: “The AUA is proud to partner with Pfizer to address critical gaps in advanced prostate cancer care.
“This initiative empowers clinicians and institutions to develop innovative solutions that enhance patient identification, optimise treatments and advance precision medicine.
“Together, we aim to improve outcomes and quality of life for patients facing this complex disease.”
Under the initiative, AUAER will lead the proposal review and evaluation process, while Pfizer, on behalf of the Pfizer-Astellas Alliance, will provide grant funding and project oversight.
Awarded organisations will independently design, implement, and manage their projects, focusing on patient outcomes in areas of unmet medical need.
The collaboration supports AUAER and Pfizer’s commitment to advancing care solutions and improving the lives of advanced prostate cancer patients.
Pfizer Maureen Doyle-Scharff said: “We are really pleased to be partnering with the American Urological Association on this quality improvement grants program which will ultimately have a positive impact on prostate cancer outcomes.
“We’re working every day to reduce health care disparities by leading and contributing to a variety of initiatives, partnerships and investments.
“The overall aim of this initiative is to support urology and medical oncology professionals so that they can improve care for patients with advanced prostate cancer.”
In August last year, Pfizer unveiled PfizerForAll, a new digital platform to provide access to healthcare and manage health and wellness for the American people.
